4.5 Article

The Longitudinal Outcome of Fibromyalgia: A Study of 1555 Patients

期刊

JOURNAL OF RHEUMATOLOGY
卷 38, 期 10, 页码 2238-2246

出版社

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.110026

关键词

FIBROMYALGIA; OUTCOME; IMPROVEMENT

资金

  1. Bristol-Myers Squibb
  2. Jazz Pharmaceuticals
  3. Boehringer Ingelheim
  4. Eli-Lilly
  5. Paladin
  6. Pfizer
  7. Purdue

向作者/读者索取更多资源

Objective. To describe the diagnosis status and outcome of patients diagnosed with fibromyalgia (FM) by US rheumatologists. Methods. We assessed 1555 patients with FM with detailed outcome questionnaires during 11,006 semiannual observations for up to 11 years. At entry, all patients satisfied American College of Rheumatology preliminary 2010 FM criteria modified for survey research. We determined diagnosis status, rates of improvement, responder subgroups, and standardized mean differences (effect sizes) between start and study completion scores of global well-being, pain, sleep problems, and health related quality of life. (QOL) Results. The 5-year improvement rates were pain 0.4 (95% CI 0.2, 0.5), fatigue 0.4 (95% CI 0.2, 0.05), and global 0.0 (95% CI -0.1, 0.1). The standardized mean differences were patient global 0.03 (95% CI -0.02,0.08), pain 0.22(95% CI 0.16, 0.28), sleep problems 0.20(95% CI 0.14, 0.25), physical component summary of the Short-form 36 (SF-36) 0.11(95% CI -0.14, -0.07), and SF-36 mental component summary 0.03 (95% CI -0.07,0.02). Patients switched between criteria-positive and criteria-negative states, with 716 patients (44.0%) failing to meet criteria at least once during 4228.5 patient-years (7448 observations). About 10% of patients had substantial improvement and about 15% had moderate improvement of pain. Overall, FM severity worsened in 35.9% and pain in 38.6%. Conclusion. Although we found no average clinically meaningful improvement in symptom severity overall, 25% had at least moderate improvement of pain over time. The result that emerged from this longitudinal study was one of generally continuing high levels of self-reported symptoms and distress for most patients, but a slight trend toward improvement. (First Release July 15 2011; J Rheumatol 2011;38:2238-46; doi:10.3899/jrheum.110026)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据